Klexane

Enoxaparin sodium, the active ingredient in Klexane, is a low molecular weight heparin presented as an injectable solution for subcutaneous, intravenous, and haemodialysis use. It prevents and treats deep vein thrombosis, pulmonary embolism, and provides anticoagulation during haemodialysis and acute coronary syndrome.

GNH USA supplies Klexane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Enoxaparin sodium is used as an anticoagulant to inhibit clot formation in venous and arterial thromboembolic conditions. - Deep vein thrombosis (DVT): prevents clot extension and recurrence in patients at risk. - Pulmonary embolism (PE): treats and reduces the risk of new embolic events. - Haemodialysis: provides anticoagulation to prevent circuit clotting during treatment. - Acute coronary syndrome (ACS): reduces clot formation associated with unstable angina or myocardial infarction. - Surgical prophylaxis: prevents postoperative venous thromboembolism in orthopedic and general surgery patients.

Enoxaparin sodium may be associated with bleeding and other adverse reactions.

Common Side Effects: - Injection site reactions: erythema, pain, or bruising at the administration site. - Minor bleeding: epistaxis, gum bleeding, or easy bruising. - Nausea: occasional gastrointestinal discomfort. - Elevated liver enzymes: mild, transient increases in hepatic transaminases.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal or external bleeding. - Thrombocytopenia: immune‑mediated platelet count drop (heparin‑induced thrombocytopenia). - Spinal/epidural hematoma: bleeding in the spinal canal after neuraxial procedures. - Allergic reactions: anaphylaxis or severe hypersensitivity.

When using enoxaparin sodium, clinicians should consider several safety precautions. - Renal impairment: adjust dose or monitor anti‑Xa levels in patients with severe kidney dysfunction. - Bleeding risk: avoid use in patients with active major bleeding or recent hemorrhagic stroke. - Concomitant anticoagulants: use caution when combined with warfarin, direct oral anticoagulants, or antiplatelet agents. - Pregnancy: category B, but weigh maternal benefits against potential fetal risks. - Surgery or invasive procedures: discontinue appropriately before procedures to reduce bleeding risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin sodium can interact with several medications, affecting anticoagulant efficacy or bleeding risk.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct thrombin inhibitors): markedly increased bleeding risk. - Antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): synergistic anticoagulation leading to severe hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: increase risk of gastrointestinal bleeding. - Thrombolytic therapy (e.g., alteplase): additive anticoagulant effect requiring close monitoring.